1. Parapouli, M.; Vasileiadis, A.; Afendra, A.S.; Hatziloukas, E. Saccharomyces cerevisiae and its industrial applications. AIMS Mi crobiol. 2020, 6, 1-31.

2. Nandy, S.K.; Srivastava, R.K. A review on sustainable yeast biotechnological processes and applications. Microbiol. Res. 2018, 207, 83-90.

3. Labussière, E.; Achard, C.S.; Dubois, S.; Combes, S.; Castex, M.; Renaudeau, D. Saccharomyces cerevisiae boulardii CNCM I-1079 supplementation in finishing male pigs helps to cope with heat stress through feeding behavior and gut microbiota modulation. Br. J. Nutr. 2021, 1-35, https://doi.org/10.1017/S0007114521001756.

4. Santos, F.D.S.; Maubrigades, L.R.; Gonçalves, V.S.; Alves Ferreira, M.R.; Brasil, C.L.; Cunha, R.C.; Conceição, F.R.; Leite, F.P.L. Immunomodulatory effect of short-term supplementation with Bacillus toyonensis BCT-7112T and Saccharomyces boulardii CNCM I-745 in sheep vaccinated with Clostridium chauvoei. Vet. Immunol. Immunopathol. 2021, 237, 110272.

5. Biswas, A.; Dev, K.; Tyagi, P.K.; Mandal, A. The effect of multi-strain probiotics as feed additives on performance, immunity, expression of nutrient transporter genes and gut morphometry in broiler chickens. Anim. Biosci. 2021. (online ahead of print).

6. McFarland, L.V. Common Organisms and Probiotics: Saccharomyces boulardii. In The Microbiota in Gastrointestinal Pathophysiol ogy: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis; Elsevier Inc.: Amsterdam, The Netherlands, 2017; pp. 145- 164; ISBN 9780128040621.

7. Pais, P.; Almeida, V.; Yılmaz, M.; Teixeira, M.C. Saccharomyces boulardii: What makes it tick as successful probiotic? J. Fungi 2020, 6, 78, doi:10.3390/jof6020078.

8. Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Gil-Campos, M.; Gil, A. Mechanisms of action of probiotics. Adv. Nutr. 2019, 10, S49-S66.

9. Constante, M.; De Palma, G.; Lu, J.; Jury, J.; Rondeau, L.; Caminero, A.; Collins, S.M.; Verdu, E.F.; Bercik, P. Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2020, 33, e13985.

10. Leventogiannis, K.; Gkolfakis, P.; Spithakis, G.; Tsatali, A.; Pistiki, A.; Sioulas, A.; Giamarellos-Bourboulis, E.J.; Triantafyllou, K. Effect of a preparation of four probiotics on symptoms of patients with Irritable Bowel Syndrome: Association with intestinal bacterial overgrowth. Probiotics Antimicrob. Proteins 2019, 11, 627-634.

11. Khatri, I.; Tomar, R.; Ganesan, K.; Prasad, G.S.; Subramanian, S. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci. Rep. 2017, 7, 1-12.

12. Peter, J.; De Chiara, M.; Friedrich, A.; Yue, J.-X.; Pflieger, D.; Bergstrom, A.; Sigwalt, A.; Barré, B.; Freel, K.; Llored, A.; et al. Genome evolution across 1,011 Saccharomyces cerevisiae isolates. Nature 2018, 556, 339-344.

13. Costa, R.L.; Moreira, J.; Lorenzo, A.; Lamas, C.C. Infectious complications following probiotic ingestion: A potentially underes timated problem? A systematic review of reports and case series. BMC Complement. Altern. Med. 2018, 18, 329, doi:10.1186/s12906-018-2394-3.

14. Ventoulis, I.; Sarmourli, T.; Amoiridou, P.; Mantzana, P.; Exindari, M.; Gioula, G.; Vyzantiadis, T.-A. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J. Fungi 2020, 6, 98, doi:10.3390/jof6030098.

15. Chakravarty, S.; Parashar, A.; Acharyya, S. Saccharomyces cerevisiae sepsis following probiotic therapy in an infant. Indian Pedi atrics 2019, 56, 971-972.

16. Imre, A.; Rácz, H.V.; Antunovics, Z.; Rádai, Z.; Kovács, R.; Lopandic, K.; Pócsi, I.; Pfliegler, W.P. A new, rapid multiplex PCR method identifies frequent probiotic origin among clinical Saccharomyces isolates. Microbiol. Res. 2019, 227, 126298.

17. Poncelet, A.; Ruelle, L.; Konopnicki, D.; Miendje Deyi, V.Y.; Dauby, N. Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration. Infect. Dis. Now 2021, 51, 293-295.

18. Edwards-Ingram, L.C.; Gent, M.E.; Hoyle, D.C.; Hayes, A.; Stateva, L.I.; Oliver, S.G. Comparative genomic hybridization pro vides new insights into the molecular taxonomy of the Saccharomyces sensu stricto complex. Genome Res. 2004, 14, 1043-1051.

19. Hennequin, C.; Thierry, A.; Richard, G.F.; Lecointre, G.; Nguyen, H.V.; Gaillardin, C.; Dujon, B. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J. Clin. Microbiol. 2001, 39, 551-559.

20. McFarland, L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 2010, 16, 2202-2222.

21. Anoop, V.; Rotaru, S.; Shwed, P.S.; Tayabali, A.F.; Arvanitakis, G. Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans. FEMS Yeast Res. 2015, 15, fov057, https://doi.org/10.1093/femsyr/fov057.

22. Clemons, K.V.; McCusker, J.H.; Davis, R.W.; Stevens, D.A. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J. Infect. Dis. 1994, 169, 859-867.

23. Klingberg, T.D.; Lesnik, U.; Arneborg, N.; Raspor, P.; Jespersen, L. Comparison of Saccharomyces cerevisiae strains of clinical and nonclinical origin by molecular typing and determination of putative virulence traits. FEMS Yeast Res. 2008, 8, 631-640.

J. Fungi 2021, 7, 746 28 of 29

24. McCusker, J.H.; Clemons, K.V.; Stevens, D.A.; Davis, R.W. Genetic characterization of pathogenic Saccharomyces cerevisiae iso lates. Genetics 1994, 136, 1261-1269.

25. de Llanos, R.; Fernández-Espinar, M.T.; Querol, A. A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors. Antonie van Leeuwenhoek 2006, 90, 221-231.

26. Zupan, J.; Raspor, P. Quantitative agar-invasion assay. J. Microbiol. Methods. 2008, 73, 100-104.

27. Pérez-Torrado, R.; Llopis, S.; Jespersen, L.; Fernández-Espinar, T.; Querol, A. Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro. Int. J. Food Microbiol. 2012, 157, 59-64.

28. Yáñez, A.; Murciano, C.; Llopis, S.; Fernández-espinar, T.; Gil, M.L.; Gozalbo, D. In vivo and in vitro studies on virulence and host responses to Saccharomyces cerevisiae clinical and non-clinical isolates. Open Mycol. J. 2009, 3, 37-47.

29. van der Aa Kühle, A.; Skovgaard, K.; Jespersen, L. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int. J. Food Microbiol. 2005, 101, 29-39.

30. Llopis, S.; Querol, A.; Heyken, A.; Hube, B.; Jespersen, L.; Fernández-Espinar, M.; Pérez-Torrado, R. Transcriptomics in human blood incubation reveals the importance of oxidative stress response in Saccharomyces cerevisiae clinical strains. BMC Genom. 2012, 13, 419, doi:10.1186/1471-2164-13-419.

31. McCullough, M.J.; Clemons, K.V.; Mccusker, J.H.; Stevens, D.A. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J. Clin. Microbiol. 1998, 36, 2613-2617.

32. de Llanos, R.; Llopis, S.; Molero, G.; Querol, A.; Gil, C.; Fernández-Espinar, M.T. In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits. Int. J. Food Microbiol. 2011, 144, 393-399.

33. Llopis, S.; Hernández-Haro, C.; Monteoliva, L.; Querol, A.; Molina, M.; Fernández-Espinar, M.T. Pathogenic potential of Sac charomyces strains isolated from dietary supplements. PLoS ONE 2014, 9, e98094.

34. Pfliegler, W.P.; Boros, E.; Pázmándi, K.; Jakab, Á.; Zsuga, I.; Kovács, R.; Urbán, E.; Antunovics, Z.; Bácsi, A.; Sipiczki, M.; et al. Commercial strain-derived clinical Saccharomyces cerevisiae can evolve new phenotypes without higher pathogenicity. Mol. Nutr. Food Res. 2017, 61, 1601099, doi:10.1002/mnfr.201601099.

35. Rácz, H.V.; Mukhtar, F.; Imre, A.; Rádai, Z.; Gombert, A.K.; Rátonyi, T.; Nagy, J.; Pócsi, I.; Pfliegler, W.P. How to characterize a strain? Clonal heterogeneity in industrial Saccharomyces influences both phenotypes and heterogeneity in phenotypes. Yeast 2021, 38, 453-470.

36. Hanna, M.; Xiao, W. Isolation of nucleic acids. Methods Mol. Biol. 2006, 313, 15-20.

37. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 2018, 35, 1547-1549.

38. Csoma, H.; Zakany, N.; Capece, A.; Romano, P.; Sipiczki, M. Biological diversity of Saccharomyces yeasts of spontaneously fer menting wines in four wine regions: Comparative genotypic and phenotypic analysis. Int. J. Food Microbiol. 2010, 140, 239-248.

39. Huxley, C.; Green, E.D.; Dunham, I. Rapid assessment of S. cerevisiae mating type by PCR. Trends Genet. 1990, 6, 236, doi:10.1016/0168-9525(90)90190-h.

40. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th ed.; CLSI standard M38; Clinical and La boratory Standards Institute: Wayne, PA, USA, 2017.

41. Luo, G.; Samaranayake, L.P.; Yau, J.Y.Y. Candida species exhibit differential in vitro hemolytic activities. J. Clin. Microbiol. 2001, 39, 2971-2974.

42. Shuster, A.; Osherov, N.; Rosenberg, M. Alcohol-mediated haemolysis in yeast. Yeast 2004, 21, 1335-1342.

43. Ohya, Y.; Sese, J.; Yukawa, M.; Sano, F.; Nakatani, Y.; Saito, T.L.; Saka, A.; Fukuda, T.; Ishihara, S.; Oka, S.; et al. High-dimen sional and large-scale phenotyping of yeast mutants. Proc. Natl. Acad. Sci. USA 2005, 102, 19015-19020.

44. Okada, H.; Ohnuki, S.; Ohya, Y. Quantification of cell, actin, and nuclear DNA morphology with high-throughput microscopy and CalMorph. Cold Spring Harb. Protoc. 2015, doi:10.1101/pdb.prot078667

45. Bauer, C.R.; Li, S.; Siegal, M.L. Essential gene disruptions reveal complex relationships between phenotypic robustness, pleiot ropy, and fitness. Mol. Syst. Biol. 2015, 11, 773.

46. Jakab, Á.; Mogavero, S.; Förster, T.M.; Pekmezovic, M.; Jablonowski, N.; Dombrádi, V.; Pócsi, I.; Hube, B. Effects of the gluco corticoid betamethasone on the interaction of Candida albicans with human epithelial cells. Microbiology 2016, 162, 2116-2125.

47. Nemes, D.; Kovács, R.; Nagy, F.; Mező, M.; Poczok, N.; Ujhelyi, Z.; Pető, Á.; Fehér, P.; Fenyvesi, F.; Váradi, J.; et al. Interaction between different pharmaceutical excipients in liquid dosage forms—Assessment of cytotoxicity and antimicrobial activity. Molecules 2018, 23, 1827, doi:10.3390/molecules23071827.

48. Fuchs, B.B.; O'Brien, E.; Khoury, J.B.E.; Mylonakis, E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 2010, 1, 475-482.

49. Lowry, R. VassarStats. Available online: http://vassarstats.net/index.html (accessed on 11 August 2021).

50. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; R Core Team: Vi enna, Austria. 2021. Available online: https://www.R-project.org/ (accessed on 3 September 2021).

51. Metsalu, T.; Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015, 43, W566-W570.

52. Statistics Kingdom: Kaplan-Meier Survival Analysis. Available online: https://www.statskingdom.com/350kaplan_meier.html (accessed on 23 July 2021).

53. Sitterlé, E.; Maufrais, C.; Sertour, N.; Palayret, M.; d'Enfert, C.; Bougnoux, M.-E. Within-host genomic diversity of Candida albi cans in healthy carriers. Sci. Rep. 2019, 9, 2563, doi:10.1038/s41598-019-38768-4.

J. Fungi 2021, 7, 746 29 of 29

54. Forche, A.; Cromie, G.; Gerstein, A.C.; Solis, N.V.; Pisithkul, T.; Srifa, W.; Jeffery, E.; Abbey, D.; Filler, S.G.; Dudley, A.M.; et al. Rapid phenotypic and genotypic diversification after exposure to the oral host niche in Candida albicans. Genetics 2018, 209, 725- 741.

55. Phadke, S.S.; Maclean, C.J.; Zhao, S.Y.; Mueller, E.A.; Michelotti, L.A.; Norman, K.L.; Kumar, A.; James, T.Y. Genome-wide screen for Saccharomyces cerevisiae genes contributing to opportunistic pathogenicity in an invertebrate model host. G3 2018, 8, 63-78.

56. Grimberg, B.; Zeyl, C. The effects of sex and mutation rate on adaptation in test tubes and to mouse hosts by Saccharomyces cerevisiae. Evolution 2005, 59, 431-438.

57. Mroczyńska, M.; Brillowska-Dąbrowska, A. Virulence of clinical Candida isolates. Pathogens 2021, 10, 466, doi:10.3390/patho gens10040466.

58. Pérez-Torrado, R.; Querol, A. Saccharomyces cerevisiae show low levels of traversal across the human blood brain barrier in vitro. F1000Research 2017, 6, 944, doi:10.12688/f1000research.11782.1.

59. Czerucka, D.; Rampal, P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World J. Gastroenterol. 2019, 25, 2188-2203.

60. Stier, H.; Bischoff, S.C. Influence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune system. Clin. Exp. Gas troenterol. 2016, 9, 269-279.

61. Smith, I.M.; Christensen, J.E.; Arneborg, N.; Jespersen, L. Yeast modulation of human dendritic cell cytokine secretion: An in vitro study. PLoS ONE 2014, 9, 12-14.

62. Di Paola, M.; Rizzetto, L.; Stefanini, I.; Vitali, F.; Massi-Benedetti, C.; Tocci, N.; Romani, L.; Ramazzotti, M.; Lionetti, P.; De Filippo, C.; et al. Comparative immunophenotyping of Saccharomyces cerevisiae and Candida spp. strains from Crohn's disease patients and their interactions with the gut microbiome. J. Transl. Autoimmun. 2020, 3, 100036.

63. Rizetto, L.; Kuka, M.; De Filippo, C.; Cambi, A.; Netea, M.G.; Beltrame, L.; Napolitani, G.; Torcia, M.G.; D'Oro, U.; Cavalieri, D. Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J. Immunol. 2010, 184, 4258-4268.

64. Kelesidis, T.; Pothoulakis, C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gas trointestinal disorders. Therap. Adv. Gastroenterol. 2012, 5, 111-125.

65. Hennequin, C.; Kauffmann-Lacroix, C.; Jobert, A.; Viard, J.P.; Ricour, C.; Jacquemin, J.L.; Berche, P. Possible role of catheters in Saccharomyces boulardii fungemia. Eur. J. Clin. Microbiol. Infect. Dis. 2000, 19, 16-20.

66. Cassone, M.; Serra, P.; Mondello, F.; Girolamo, A.; Scafetti, S.; Pistella, E.; Venditti, M. Outbreak of Saccharomyces cerevisiae Subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J. Clin. Microbiol. 2003, 41, 5340-5343.

67. Cohen, L.; Ranque, S.; Raoult, D. Saccharomyces cerevisiae boulardii transient fungemia after intravenous self-inoculation. Med. Mycol. Case Rep. 2013, 2, 63-64.

68. Fadhel, M.; Patel, S.; Liu, E.; Levitt, M.; Asif, A. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med. Mycol. Case Rep. 2019, 23, 23-25.

69. Dauby, N. Risks of Saccharomyces boulardii-containing probiotics for the prevention of Clostridium difficile Infection in the elderly. Gastroenterology 2017, 153, 1450-1451.

70. Ragonnaud, E.; Biragyn, A. Gut microbiota as the key controllers of “healthy” aging of elderly people. Immun. Ageing. 2021, 18, 2, doi:10.1186/s12979-020-00213-w.

71. Santino, I.; Alari, A.; Bono, S.; Teti, E.; Marangi, M.; Bernardini, A.; Magrini, L.; Di Somma, S.; Teggi, A. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int. J. Immunopathol. Phar macol. 2014, 27, 143-146.